Nectin Therapeutics Ltd., a Jerusalem, Israel- and Fort lee, NJ-based based biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments, raised $5.4m in funding.
Cancer Focus Fund, LP, an investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson), provided the funding.
The company intends to use the funds to advance a Phase 1 clinical trial of Nectin’s PVR blocker, NTX1088, in cancer patients with locally advanced and metastatic solid tumors.
Led by Fabian Tenenbaum, Chief Executive Officer, Nectin Therapeutics is a biotechnology company leveraging insights into the nectin pathway to develop immune oncology (IO) therapies. The technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.
NTX1088 is a high affinity monoclonal antibody directed against PVR, an immune checkpoint ligand. NTX1088 blocks the signaling of the immune checkpoint receptors TIGIT and CD96, while restoring the expression and immune function of DNAM1 (CD226), resulting in increased anti-tumor immune effects from activated T cells and natural killer (NK) cells in the tumor microenvironment.
Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, Integra Holdings and Cancer Focus Fund.
The Phase 1 trial is expected to begin enrolling patients around mid-year of 2022.
FinSMEs
09/03/2022